deferoxamine has been researched along with Acidosis in 10 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Acidosis: A pathologic condition of acid accumulation or depletion of base in the body. The two main types are RESPIRATORY ACIDOSIS and metabolic acidosis, due to metabolic acid build up.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Incomplete cerebral ischemia was produced by intracranial pressure elevation for 30 minutes with plasma glucose at 540 +/- 15 mg/dL." | 5.29 | Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. ( Blizzard, KK; Hurn, PD; Koehler, RC; Traystman, RJ, 1995) |
| " Monensin potentiated the cell killing, and extracellular acidosis prevented it." | 3.68 | The killing of cultured hepatocytes by N-acetyl-p-benzoquinone imine (NAPQI) as a model of the cytotoxicity of acetaminophen. ( Farber, JL; Harman, AW; Kyle, ME; Serroni, A, 1991) |
| "Incomplete cerebral ischemia was produced by intracranial pressure elevation for 30 minutes with plasma glucose at 540 +/- 15 mg/dL." | 1.29 | Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. ( Blizzard, KK; Hurn, PD; Koehler, RC; Traystman, RJ, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pietra, V | 1 |
| Degrassi, S | 1 |
| Fusi-Schmidhauser, T | 1 |
| Simonse, E | 1 |
| Valk-Swinkels, CG | 1 |
| van 't Veer, NE | 1 |
| Ermens, AA | 1 |
| Veldkamp, EJ | 1 |
| WHITTEN, CF | 1 |
| Hurn, PD | 1 |
| Koehler, RC | 1 |
| Blizzard, KK | 1 |
| Traystman, RJ | 1 |
| Tsai, KL | 1 |
| Wang, SM | 1 |
| Chen, CC | 1 |
| Fong, TH | 1 |
| Wu, ML | 1 |
| Ying, W | 1 |
| Han, SK | 1 |
| Miller, JW | 1 |
| Swanson, RA | 1 |
| Harman, AW | 1 |
| Kyle, ME | 1 |
| Serroni, A | 1 |
| Farber, JL | 1 |
| Santos, F | 1 |
| Massie, MD | 1 |
| Chan, JC | 1 |
| Robertson, WO | 1 |
| Lavender, S | 1 |
| Bell, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomized, Placebo Controlled, Dose-finding Phase 2 Clinical Trial of Intravenous Deferoxamine in Patients With Acute Ischemic Stroke Treated With Tissue Plasminogen Activator[NCT00777140] | Phase 2 | 62 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for deferoxamine and Acidosis
| Article | Year |
|---|---|
Risk factors in aluminum toxicity in children with chronic renal failure.
Topics: Acidosis; Adolescent; Adult; Aluminum; Aluminum Hydroxide; Bone and Bones; Child; Citrates; Citric A | 1986 |
Treatment of acute iron poisoning.
Topics: Acidosis; Acute Disease; Bicarbonates; Deferoxamine; Diarrhea; Edetic Acid; Emetics; Humans; Infusio | 1971 |
8 other studies available for deferoxamine and Acidosis
| Article | Year |
|---|---|
The Dark Side of Iron.
Topics: Acidosis; Adolescent; Anemia, Iron-Deficiency; Deferoxamine; Drug Overdose; Female; Ferrous Compound | 2020 |
Iron autointoxication in a 16-year-old girl: a protective role for hepcidin?
Topics: Acidosis; Adolescent; Antimicrobial Cationic Peptides; Deferoxamine; Female; Ferrous Compounds; Hema | 2013 |
ACCIDENTAL IRON POISONING IN CHILDREN.
Topics: Accident Prevention; Acidosis; Bicarbonates; Chelating Agents; Child; Deferoxamine; Dogs; Humans; Hy | 1963 |
Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs.
Topics: Acidosis; Adenosine Triphosphate; Animals; Brain Ischemia; Deferoxamine; Disease Models, Animal; Dog | 1995 |
Mechanism of oxidative stress-induced intracellular acidosis in rat cerebellar astrocytes and C6 glioma cells.
Topics: Acidosis; Adenosine Triphosphate; Animals; Astrocytes; Catalase; Cells, Cultured; Cerebellum; Citric | 1997 |
Acidosis potentiates oxidative neuronal death by multiple mechanisms.
Topics: Acidosis; Amidines; Animals; Animals, Newborn; Cell Death; Cells, Cultured; Chelating Agents; Defero | 1999 |
The killing of cultured hepatocytes by N-acetyl-p-benzoquinone imine (NAPQI) as a model of the cytotoxicity of acetaminophen.
Topics: Acetaminophen; Acidosis; Adenosine Triphosphate; Animals; Benzoflavones; Benzoquinones; beta-Naphtho | 1991 |
Iron intoxication in an adult.
Topics: Acidosis; Adult; Anuria; Deferoxamine; Female; Humans; Iron; Peritoneal Dialysis; Poisoning; Shock, | 1970 |